Alzheimer's disease (AD) has been genetically and pathologically associated with neuroinflammation. Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor involved in innate immunity. TREM2 rare protein coding genetic variants have been linked to AD. A soluble TREM2 (sTREM2) cleavage product is elevated in AD. It is unclear whether there is a relationship between elevated sTREM2 and markers of inflammation. The hypothesis of this investigation was that central and peripheral inflammation play a role in sTREM2 levels in AD. A consistent association of peripheral or central markers of inflammation and CSF sTREM2 levels was not found, suggesting a limited impact of general inflammation on sTREM2 levels. An association between peripheral sTREM2 levels and CSF sTREM2, as well as an association between CSF sTREM2 and a marker of blood brain barrier integrity, was observed in AD, suggesting a potential role of peripheral TREM2 in central TREM2 biology.
Introduction
Triggering receptor expressed on myeloid cells 2 (TREM2) is part of the immunoglobulin-lectin-like receptor superfamily. The TREM2 gene is part of a family of receptors that are clustered together on human chromosome 6. These receptors participate in various cellular processes such as inflammation, phagocytosis, bone homeostasis, and neural development (Takahashi et al., 2007; Jay et al., 2015a; Jay et al., 2017) . Genetic mutations in TREM2 cause the autosomal recessive disorder Nasu-Hakola disease (also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy) (Kondo et al., 2002; Chouery et al., 2008) . Carriers of the TREM2 R47H genetic variant have an increased risk for developing Alzheimer's disease (AD) (Jonsson et al., 2013; Guerreiro et al., 2013) and have a possible, but inconsistent increased risk for Parkinson's disease (PD) (Rayaprolu et al., 2013; Lill et al., 2015) .
TREM2 is expressed on the cell surface of microglia, macrophages, osteoclasts, and dendritic cells, as well as bronchial epithelial cells, fibroblasts, and lung adenocarcinoma cells (Yaghmoor et al., 2014) . TREM2 is involved in the activation of monocyte-derived dendritic cells, osteoclast development, enhancement of chemotaxis, and reduction of pro-inflammatory cytokine release while promoting antiinflammatory cytokine expression (Klesney-Tait et al., 2006; Neumann and Takahashi, 2007) . In the brain, TREM2 is expressed mainly in microglial cells and has been linked to phagocytosis, cell growth, regulation of actin cytoskeleton, migration towards chemokines, and cytokine release (Painter et al., 2015; Walter, 2016) . Ligands for TREM2 have not been verified to date; however, there is evidence that TREM2 interacts with apolipoproteins such as apoE and apoJ, Aβ, various anions, lipids, and hsp60 (Stefano et al., 2009; Atagi et al., 2015; Zhong et al., 2017; Jendresen et al., 2017) .
TREM2 transcripts and protein levels in blood and brain are elevated in AD patients compared to cognitively normal controls (Hu et al., 2014; Ma et al., 2016) . TREM2 isoforms have been described including alternatively spliced isoforms and an isoform that is the result of cleavage at the membrane-spanning domain by ADAM10 or ADAM17 to produce a soluble TREM2 (sTREM2) protein fragment (Ma et al., 2016; Begum et al., 2004; Thornton et al., 2017; Schlepckow et al., 2017; Jin et al., 2014; Celarain et al., 2016) . These isoforms have been described in various human biofluids, tissues and cell types, such as cerebrospinal fluid (CSF), plasma, monocytes, microglia and brain (Ma et al., 2016; Begum et al., 2004; Thornton et al., 2017; Schlepckow et al., 2017; Jin et al., 2014 
